Haydinger Cameron D, Ferreira Lisia Barros, Williams Keryn A, Smith Justine R
Flinders University College of Medicine and Public Health, Adelaide, SA, Australia.
Front Med (Lausanne). 2023 Mar 7;10:1128811. doi: 10.3389/fmed.2023.1128811. eCollection 2023.
Macular edema is the pathological accumulation of fluid in the central retina. It is a complication of many retinal diseases, including diabetic retinopathy, retinal vascular occlusions and uveitis, among others. Macular edema causes decreased visual acuity and, when chronic or refractory, can cause severe and permanent visual impairment and blindness. In most instances, it develops due to dysregulation of the blood-retinal barrier which permits infiltration of the retinal tissue by proteins and other solutes that are normally retained in the blood. The increase in osmotic pressure in the tissue drives fluid accumulation. Current treatments include vascular endothelial growth factor blockers, corticosteroids, and non-steroidal anti-inflammatory drugs. These treatments target vasoactive and inflammatory mediators that cause disruption to the blood-retinal barrier. In this review, a clinical overview of macular edema is provided, mechanisms of disease are discussed, highlighting processes targeted by current treatments, and areas of opportunity for future research are identified.
黄斑水肿是指视网膜中央病理性液体积聚。它是许多视网膜疾病的并发症,包括糖尿病性视网膜病变、视网膜血管阻塞和葡萄膜炎等。黄斑水肿会导致视力下降,若为慢性或难治性,可导致严重且永久性的视力损害甚至失明。在大多数情况下,它是由于血视网膜屏障失调所致,这使得通常保留在血液中的蛋白质和其他溶质渗入视网膜组织。组织中渗透压的升高促使液体蓄积。目前的治疗方法包括血管内皮生长因子阻滞剂、皮质类固醇和非甾体抗炎药。这些治疗针对的是导致血视网膜屏障破坏的血管活性和炎症介质。在本综述中,提供了黄斑水肿的临床概述,讨论了疾病机制,强调了当前治疗所针对的过程,并确定了未来研究的机会领域。